| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Over the last 12 months, insiders at Cocrystal Pharma, Inc. have bought $0 and sold $0 worth of Cocrystal Pharma, Inc. stock.
On average, over the past 5 years, insiders at Cocrystal Pharma, Inc. have bought $1.02M and sold $1.7M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,015,229 shares for transaction amount of $2M was made by FROST PHILLIP MD ET AL () on 2023‑04‑04.
| 2023-04-04 | FROST PHILLIP MD ET AL | 1.02M 11.981% | $1.97 | $2M | -5.85% | |||
| 2021-08-20 | PFENNIGER RICHARD C JR | director | 40,000 0.0414% | $1.03 | $41,120 | -46.08% | ||
| 2021-05-04 | Sale | Schinazi Raymond F | 10 percent owner | 575,000 0.9104% | $2.95 | $1.7M | -56.54% | |
| 2019-10-25 | Schinazi Raymond F | 10 percent owner | 7,906 0.0202% | $1.15 | $9,092 | -14.81% | ||
| 2019-10-24 | Schinazi Raymond F | 10 percent owner | 5,094 0.0122% | $1.15 | $5,858 | -20.00% | ||
| 2019-10-23 | Schinazi Raymond F | 10 percent owner | 3,935 0.0085% | $1.04 | $4,087 | -20.00% | ||
| 2016-12-23 | Sale | Lee Sam | 2.2M 0.343% | $0.44 | $968,000 | -37.50% | ||
| 2016-09-01 | WILCOX GARY | 10,000 0.0015% | $0.41 | $4,100 | -30.00% | |||
| 2016-09-01 | Schinazi Raymond F | 4.88M 0.7103% | $0.41 | $2M | -30.00% | |||
| 2016-09-01 | BLOCK DAVID S | 10,000 0.0015% | $0.41 | $4,100 | -30.00% | |||
| 2016-03-15 | Schinazi Raymond F | 2.94M 0.3532% | $0.51 | $1.5M | -22.95% | |||
| 2016-03-15 | FROST PHILLIP MD ET AL | 2.94M 0.3532% | $0.51 | $1.5M | -22.95% | |||
| 2016-03-15 | WILCOX GARY | 49,020 0.0059% | $0.51 | $25,000 | -22.95% | |||
| 2016-03-15 | HSIAO JANE PH D | 1.24M 0.1484% | $0.51 | $630,000 | -22.95% | |||
| 2016-03-15 | Rubin Steven D | 39,216 0.0047% | $0.51 | $20,000 | -22.95% | |||
| 2016-03-15 | Meckler Jeffrey A | 294,118 0.0353% | $0.51 | $150,000 | -22.95% | |||
| 2016-03-15 | BLOCK DAVID S | 50,000 0.006% | $0.51 | $25,500 | -22.95% | |||
| 2015-12-23 | Meckler Jeffrey A | 100,000 0.0151% | $0.58 | $57,870 | -3.64% | |||
| 2015-04-21 | Schinazi Raymond F | 3.46M 0.4605% | $0.92 | $3.19M | -26.00% | |||
| 2015-03-25 | FROST PHILLIP MD ET AL | 3.46M 0.4593% | $0.92 | $3.19M | -22.77% |
| WILCOX GARY | 16948605 166.5907% | $25.68M | 3 | 0 | ||
| Lee Sam | 13087847 128.6427% | $19.83M | 0 | 1 | ||
| Schinazi Raymond F | 10 percent owner | 7674960 75.4385% | $11.63M | 6 | 1 | <0.0001% |
| HSIAO JANE PH D | 3435294 33.7661% | $5.2M | 2 | 0 | ||
| FROST PHILLIP MD ET AL | 1319838 12.9729% | $2M | 6 | 0 | <0.0001% | |
| Rubin Steven D | 733484 7.2095% | $1.11M | 2 | 0 | ||
| Meckler Jeffrey A | 657161 6.4593% | $995,598.92 | 4 | 0 | ||
| BLOCK DAVID S | 168696 1.6581% | $255,574.44 | 3 | 0 | ||
| PFENNIGER RICHARD C JR | director | 40000 0.3932% | $60,600.00 | 1 | 0 | <0.0001% |
$85,897,100 | 36 | 2.47% | $16.89M | |
$226,127 | 22 | -27.62% | $14.26M | |
$547,862 | 19 | -29.82% | $14.3M | |
$2,553,853 | 17 | 16.69% | $14.32M | |
$122,973 | 15 | -26.96% | $15.8M | |
$39,336,371 | 14 | -17.87% | $14.39M | |
$389,864 | 11 | 12.52% | $13.84M | |
$70,584,874 | 10 | 3.97% | $15.76M | |
$20,715,938 | 10 | -42.51% | $19.16M | |
$189,648 | 9 | -52.20% | $17.12M | |
$456,220 | 9 | 34.12% | $19.3M | |
$2,891,537 | 8 | -39.31% | $14.92M | |
Cocrystal Pharma, Inc. (COCP) | $2,060,158 | 5 | -21.35% | $15.41M |
$26,000,000 | 5 | -56.00% | $19.43M | |
$82,917 | 4 | -11.54% | $19.09M | |
$45,953 | 2 | -2.14% | $13.57M | |
$45,452 | 2 | -43.22% | $13.76M | |
$44,529 | 2 | -30.33% | $15.69M | |
$5,512,500 | 1 | -7.91% | $14.26M |
| Increased Positions | 7 | +25% | 106,894 | +15.02% |
| Decreased Positions | 8 | -28.57% | 69,527 | -9.77% |
| New Positions | 2 | New | 69,305 | New |
| Sold Out Positions | 3 | Sold Out | 10,020 | Sold Out |
| Total Postitions | 27 | -3.57% | 748,824 | +5.25% |
| Vanguard Group Inc | $441.00 | 2.76% | 275,656 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $201.00 | 1.26% | 125,828 | -4,200 | -3.23% | 2024-12-31 |
| Blackrock, Inc. | $118.00 | 0.74% | 73,746 | 0 | 0% | 2025-03-31 |
| Geode Capital Management, Llc | $110.00 | 0.69% | 68,890 | +2,630 | +3.97% | 2024-12-31 |
| Morgan Stanley | $103.00 | 0.64% | 64,346 | +5,046 | +8.51% | 2024-12-31 |
| State Street Corp | $33.00 | 0.21% | 20,543 | 0 | 0% | 2024-12-31 |
| Parallel Advisors, Llc | $24.00 | 0.15% | 15,228 | 0 | 0% | 2025-03-31 |
| Dimensional Fund Advisors Lp | $24.00 | 0.15% | 15,015 | +923 | +6.55% | 2024-12-31 |
| Northern Trust Corp | $19.00 | 0.12% | 12,171 | 0 | 0% | 2024-12-31 |
| Susquehanna International Group, Llp | $19.00 | 0.12% | 12,127 | -25,673 | -67.92% | 2024-12-31 |